USES. RINVOQ is a prescription medicine used to treat: Adults with moderate to severe rheumatoid arthritis (RA) when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated.

RINVOQ works quickly - in as little as 1 week for some people - to help relieve RA pain, swelling, and stiffness. The majority of people taking RINVOQ had significantly improved symptoms at 12 weeks.

RINVOQ is a JAK inhibitor For adults with moderate to severe rheumatoid arthritis (RA) in whom TNF blockers did not work well.

Rinvoq has an average rating of 6.3 out of 10 from a total of 130 reviews on Drugs.com. 50% of reviewers reported a positive experience, while 29% reported a negative experience.

RINVOQ may increase your risk of certain cancers. Lymphoma and other cancers, including skin cancers, can happen. Current or past smokers are at higher risk of certain cancers, including lymphoma and lung cancer. Follow your HCP's advice about having your skin checked for skin cancer during treatment with RINVOQ.

Following eight weeks of Rinvoq treatment, 23 of 27 (85.2%) patients with ulcerative colitis experienced a clinical response and 22 of 27 (81.5%) experienced clinical remission.

In the induction studies, a greater proportion of patients treated with RINVOQ 45 mg once daily compared to placebo had no bowel urgency (U‑ACHIEVE: 48% vs 21%, U‑ACCOMPLISH: 54% vs 26%) at Week 8. At Day 1, 17% of patients on RINVOQ 45 mg reported no bowel urgency vs 13% on placebo.

Rinvoq's recommended starting dosage for Crohn's disease is 45 mg once per day for 12 weeks. Then your doctor will lower your dosage. The typical maintenance dosage is 15 mg once per day. If needed, your doctor may increase it to 30 mg once per day.

Generic Name: upadacitinib. Upadacitinib is used to treat certain types of arthritis (such as psoriatic arthritis, rheumatoid arthritis, axial spondyloarthritis). It helps decrease pain, tenderness, and swelling in the joints. Upadacitinib is also used to treat a skin condition called atopic dermatitis.

In patients ≥65 years of age, there is an increased risk of adverse reactions with RINVOQ 30 mg once daily. Consequently, the recommended dose for long-term use in this patient population is 15 mg once daily. Use in combination with other potent immunosuppressants is not recommended.

Continue taking your medicine for as long as your doctor tells you. This medicine helps to control your condition but does not cure it. It is important to keep taking your medicine even if you feel well. It is important that you do not skip doses of Rinvoq.

RINVOQ is used to treat adults with moderate to severe rheumatoid arthritis when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated. It is not known if RINVOQ is safe and effective in children with juvenile idiopathic arthritis.